Munerato Patrícia, Azevedo Maria Lúcia, Sucupira Maria Cecília Araripe, Pardini Regina, Pinto Gedson Humberto Novaes, Catroxo Márcia, Souza Inara Espinelli, Diaz Ricardo Sobhie
Retrovirology Laboratory, Federal University of São Paulo, São Paulo, SP, Brazil.
Braz J Infect Dis. 2003 Aug;7(4):236-40. doi: 10.1590/s1413-86702003000400002.
Entry of human immunodeficiency type 1 virus (HIV-1) into target cells requires both CD(4)and one of the chemokine receptors. Viruses predominantly use one, or occasionally both, of the major co-receptors CCR5 and CXCR4, although other receptors, including CCR2B and CCR3, function as minor co-receptors. A 32-nucleotide deletion (D32) within the b-chemokine receptor 5 gene (CCR5) has been described in subjects who remain uninfected despite extensive exposition to HIV-1. The heterozygous genotype delays disease progression. This allele is common among Caucasians, but has not been found in people of African or Asian ancestry. A more common transition involving a valine to isoleucine switch in transmembrane domain I of CCR2B (64I), with unknown functional consequences, was found to delay disease progression but not to reduce infection risk. As the Brazilian population consists of a mixture of several ethnic groups, we decided to examine the genotype frequency of these polymorphisms in this country. There were 11.5% CCR5 heterozygotes among the HIV-1 infected population and 12.5% among uninfected individuals, similar to data from North America and Western Europe. The prevalence of CCR2-64I homozygotes and heterozygotes was 0.06 and 15.2%, respectively, also similar to what is known for North America and Western Europe.
人类免疫缺陷病毒1型(HIV-1)进入靶细胞既需要CD4,也需要一种趋化因子受体。病毒主要使用主要共受体CCR5和CXCR4中的一种,偶尔也会使用两种,不过其他受体,包括CCR2B和CCR3,作为次要共受体发挥作用。在尽管大量接触HIV-1却仍未感染的个体中,已发现β趋化因子受体5基因(CCR5)内存在一个32个核苷酸的缺失(D32)。杂合基因型会延缓疾病进展。该等位基因在高加索人中很常见,但在非洲或亚洲血统的人群中未发现。在CCR2B的跨膜结构域I中发现了一种更常见的缬氨酸到异亮氨酸转换(64I),其功能后果未知,发现它会延缓疾病进展,但不会降低感染风险。由于巴西人口由多个种族群体混合而成,我们决定研究该国这些多态性的基因型频率。在HIV-1感染人群中,CCR5杂合子占比11.5%,未感染个体中占比12.5%,这与北美和西欧的数据相似。CCR2-64I纯合子和杂合子的患病率分别为0.06%和15.2%,也与北美和西欧已知情况相似。